Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CATHY ENG and MICHAEL JAMES OVERMAN.
CATHY ENG
Connection Strength
3.241
MICHAEL JAMES OVERMAN
  1. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
    View in: PubMed
    Score: 0.212
  2. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol. 2017 Nov; 24(12):3667-3672.
    View in: PubMed
    Score: 0.150
  3. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017 05 15; 17(1):331.
    View in: PubMed
    Score: 0.147
  4. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11; 7(41):67495-67506.
    View in: PubMed
    Score: 0.141
  5. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist. 2015 Mar; 20(3):e3-4.
    View in: PubMed
    Score: 0.126
  6. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84.
    View in: PubMed
    Score: 0.125
  7. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7.
    View in: PubMed
    Score: 0.115
  8. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013 Jun; 257(6):1072-8.
    View in: PubMed
    Score: 0.112
  9. Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. Acta Oncol. 2013 Jun; 52(5):1044-6.
    View in: PubMed
    Score: 0.107
  10. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11(3):191-4.
    View in: PubMed
    Score: 0.102
  11. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012 Mar; 23(3):652-658.
    View in: PubMed
    Score: 0.098
  12. Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res. 2011 Jul 01; 17(13):4531-40.
    View in: PubMed
    Score: 0.097
  13. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer. 2011 Sep; 10(3):198-202.
    View in: PubMed
    Score: 0.097
  14. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55.
    View in: PubMed
    Score: 0.090
  15. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010 Jan 15; 116(2):316-22.
    View in: PubMed
    Score: 0.089
  16. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.
    View in: PubMed
    Score: 0.083
  17. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42.
    View in: PubMed
    Score: 0.081
  18. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5.
    View in: PubMed
    Score: 0.079
  19. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316161.
    View in: PubMed
    Score: 0.056
  20. Publisher Correction: A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep. 2023 May 23; 13(1):8318.
    View in: PubMed
    Score: 0.056
  21. A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep. 2022 11 08; 12(1):19023.
    View in: PubMed
    Score: 0.054
  22. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open. 2022 05 02; 5(5):e2213588.
    View in: PubMed
    Score: 0.052
  23. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol. 2022 Apr; 13(2):647-656.
    View in: PubMed
    Score: 0.052
  24. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. 2020 10; 123(8):1262-1270.
    View in: PubMed
    Score: 0.046
  25. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199.
    View in: PubMed
    Score: 0.046
  26. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.
    View in: PubMed
    Score: 0.046
  27. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.043
  28. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.043
  29. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.038
  30. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018 06; 67(6):1095-1102.
    View in: PubMed
    Score: 0.038
  31. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. 2017 Dec; 24(13):4051-4058.
    View in: PubMed
    Score: 0.038
  32. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.
    View in: PubMed
    Score: 0.038
  33. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol. 2017 Sep; 24(9):2646-2654.
    View in: PubMed
    Score: 0.037
  34. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
    View in: PubMed
    Score: 0.037
  35. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8).
    View in: PubMed
    Score: 0.037
  36. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154.
    View in: PubMed
    Score: 0.036
  37. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One. 2017; 12(3):e0173345.
    View in: PubMed
    Score: 0.036
  38. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151.
    View in: PubMed
    Score: 0.036
  39. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol. 2017 Jan; 24(1):187-193.
    View in: PubMed
    Score: 0.035
  40. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
    View in: PubMed
    Score: 0.035
  41. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8.
    View in: PubMed
    Score: 0.031
  42. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-2014.
    View in: PubMed
    Score: 0.030
  43. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.030
  44. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014 May; 22(5):1223-31.
    View in: PubMed
    Score: 0.029
  45. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.
    View in: PubMed
    Score: 0.029
  46. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90.
    View in: PubMed
    Score: 0.024
  47. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
    View in: PubMed
    Score: 0.022
  48. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83.
    View in: PubMed
    Score: 0.021
  49. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
    View in: PubMed
    Score: 0.020
  50. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.